Quarterly report [Sections 13 or 15(d)]

Fair Value of Financial Instruments - Summary of contingent consideration related to acquisition (Details)

v3.25.3
Fair Value of Financial Instruments - Summary of contingent consideration related to acquisition (Details) - USD ($)
3 Months Ended 9 Months Ended
Feb. 21, 2025
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
Business Combination [Line Items]          
Balance, beginning       $ 0  
Change in fair value contingent consideration $ (4,435,443) $ (492,827) $ 0 (2,016,111) $ 0
Balance, ending   2,419,332   2,419,332  
CorHepta [Member]          
Business Combination [Line Items]          
Balance, beginning   2,912,159 0 0 0
Additions   0 0 4,435,443 0
Payments   0 0 0 0
Change in fair value contingent consideration   (492,827) 0 (2,016,111) 0
Balance, ending   $ 2,419,332 $ 0 $ 2,419,332 $ 0